Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)

Clinical Chemistry
Valentine Charlton-MenysPaul N Durrington

Abstract

LDL can vary considerably in its cholesterol content; thus, lowering LDL cholesterol (LDLC) as a goal of statin treatment implies the existence of considerable variation in the extent to which statin treatment removes circulating LDL particles. This consideration is particularly applicable in diabetes mellitus, in which LDL is frequently depleted of cholesterol. Type 2 diabetes patients randomly allocated to 10 mg/day atorvastatin (n = 1154) or to placebo (n = 1196) for 1 year were studied to compare spontaneous and statin-induced apolipoprotein B (apo B) concentrations (a measure of LDL particle concentration) at LDLC and non-HDL cholesterol (non-HDLC) concentrations proposed as statin targets in type 2 diabetes. Patients treated with atorvastatin produced lower serum apo B concentrations at any given LDLC concentration than patients on placebo. An LDLC concentration of 1.8 mmol/L (70 mg/dL) during atorvastatin treatment was equivalent to a non-HDLC concentration of 2.59 mmol/L (100 mg/dL) or an apo B concentration of 0.8 g/L. At the more conservative LDLC targets of 2.59 mmol/L (100 mg/dL) and 3.37 mmol/L (130 mg/dL) for non-HDLC, however, the apo B concentration exceeded the 0.9-g/L value anticipated in the recent Consensus ...Continue Reading

References

Dec 1, 1991·The Journal of Clinical Investigation·J L Witztum, D Steinberg
Oct 7, 1988·JAMA : the Journal of the American Medical Association·M A AustinR M Krauss
Jul 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·D W BilheimerJ L Goldstein
Jan 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·A SnidermanP O Kwiterovich
Oct 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·G FranceschiniC R Sirtori
Feb 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·A GawJ Shepherd
Jul 27, 2001·The American Journal of Cardiology·C M BallantyneUNKNOWN ACCESS Study Group. Atorvastatin Comparative Cholesterol Efficacy and Safety Study
Mar 29, 2002·Diabetic Medicine : a Journal of the British Diabetic Association·H M ColhounUNKNOWN Collaborative AtoRvastatin Diabetes Study (CARDS)
May 27, 2004·Diabetes Care·Ronald M Krauss
Aug 21, 2007·JAMA : the Journal of the American Medical Association·Erik IngelssonRamachandran S Vasan
Sep 21, 2007·Atherosclerosis·Ian GrahamUNKNOWN ESC Committee for Practice Guidelines

❮ Previous
Next ❯

Citations

Nov 26, 2013·Current Atherosclerosis Reports·Benoit J Arsenault, S Matthijs Boekholdt
Feb 11, 2012·Current Diabetes Reports·Jeffrey I MechanickOsama Hamdy
Jun 30, 2011·European Heart Journal·UNKNOWN European Association for Cardiovascular Prevention & RehabilitationUNKNOWN ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees
Jan 27, 2010·Current Opinion in Lipidology·Srinivasa P Munigoti, Alan Rees
Oct 15, 2009·Diabetology & Metabolic Syndrome·Themis ZelmanovitzLuís H Canani
Dec 14, 2011·Clinical Lipidology·Danyaal S Moin, Anand Rohatgi
Sep 16, 2014·Current Medical Research and Opinion·Khalid Al-RasadiMahmoud Alawadhi
May 16, 2014·Canadian Journal of Diabetes·G B John ManciniLawrence A Leiter
Feb 15, 2012·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Kathleen E CoreyRaymond T Chung
Nov 26, 2011·Revista española de cardiología·Željko ReinerUNKNOWN Clinical Practice Guidelines Committee of the Spanish Society of Cardiology
May 4, 2010·Mayo Clinic Proceedings·Charles R Harper, Terry A Jacobson
Oct 9, 2015·International Journal of Cardiology·Evangelos OikonomouDimitris Tousoulis
Feb 4, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·L SibalP D Home
Jan 19, 2016·Current Opinion in Lipidology·Rutger VerbeekS Matthijs Boekholdt
May 21, 2016·Nature Reviews. Endocrinology·Katrina L EllisGerald F Watts
Jun 1, 2016·Cardiovascular Drugs and Therapy·Robert S RosensonMichael Miller
Aug 28, 2016·European Heart Journal·Alberico L CatapanoUNKNOWN ESC Scientific Document Group
Apr 16, 2015·European Journal of Preventive Cardiology·Petri T Kovanen, Matti Jauhiainen
Sep 18, 2015·Arteriosclerosis, Thrombosis, and Vascular Biology·Robert A HegeleFrancine K Welty
Aug 15, 2015·Circulation. Cardiovascular Genetics·Audrey Y ChuDaniel I Chasman
May 29, 2009·Current Opinion in Lipidology·Allan Sniderman
May 16, 2018·Clinical Chemistry·Michel R LangloisUNKNOWN European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Join
Jun 21, 2019·Current Opinion in Lipidology·Handrean SoranPaul N Durrington
Sep 11, 2019·European Heart Journal·François MachUNKNOWN ESC Scientific Document Group
Sep 10, 2019·European Heart Journal·Francesco CosentinoUNKNOWN ESC Scientific Document Group
Oct 9, 2019·Atherosclerosis·UNKNOWN Authors/Task Force MembersUNKNOWN ESC National Cardiac Societies
Aug 10, 2021·Practical Laboratory Medicine·Subashini C Thambiah, Leslie Charles Lai
Jun 11, 2010·Current Opinion in Cardiology

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.